Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...
AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.
This report, published by Towards Healthcare, a sister firm of Precedence Research, provides an in-depth analysis of the ...
Pharmaceutical Technology on MSN
Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal
MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...
REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related ...
MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...
MeiraGTx Holdings Receives RMAT Designation from FDA for AAV-GAD Gene Therapy in Parkinson's Disease
MeiraGTx Holdings plc announced that the FDA has granted its investigational gene therapy AAV-GAD the Regenerative Medicine Advanced Therapy (RMAT) designation for treating Parkinson's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback